Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology RaceLarge pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant to enter the oncology race with its $1.4 billion acquisition of Point Biopharma Global, a company specializing in precise radioligand therapies for cancer. Earlier this year, Pfizer … Continue reading "Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race"
